ATE309998T1 - Pharmazeutisch wirksamer sulfonamid derivaten - Google Patents

Pharmazeutisch wirksamer sulfonamid derivaten

Info

Publication number
ATE309998T1
ATE309998T1 AT00960921T AT00960921T ATE309998T1 AT E309998 T1 ATE309998 T1 AT E309998T1 AT 00960921 T AT00960921 T AT 00960921T AT 00960921 T AT00960921 T AT 00960921T AT E309998 T1 ATE309998 T1 AT E309998T1
Authority
AT
Austria
Prior art keywords
pharmaceutically active
sulfonamide derivatives
active sulfonamide
derivatives
pharmaceutically
Prior art date
Application number
AT00960921T
Other languages
English (en)
Inventor
Stephen Arkinstall
Serge Halazy
Dennis Church
Montserrat Camps
Thomas Rueckle
Jean-Pierre Gotteland
Marco Biamonte
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE309998T1 publication Critical patent/ATE309998T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/34—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00960921T 1999-09-28 2000-09-28 Pharmazeutisch wirksamer sulfonamid derivaten ATE309998T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99810869A EP1088821A1 (de) 1999-09-28 1999-09-28 Pharmazeutisch wirksamer Sulfonamid Derivate
PCT/IB2000/001380 WO2001023378A1 (en) 1999-09-28 2000-09-28 Pharmaceutically active sulfonamide derivatives

Publications (1)

Publication Number Publication Date
ATE309998T1 true ATE309998T1 (de) 2005-12-15

Family

ID=8243049

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00960921T ATE309998T1 (de) 1999-09-28 2000-09-28 Pharmazeutisch wirksamer sulfonamid derivaten

Country Status (30)

Country Link
US (1) US8012995B1 (de)
EP (2) EP1088821A1 (de)
JP (2) JP5015397B2 (de)
KR (1) KR100827533B1 (de)
CN (1) CN1189467C (de)
AR (1) AR031531A1 (de)
AT (1) ATE309998T1 (de)
AU (1) AU777708B2 (de)
BG (1) BG65797B1 (de)
BR (1) BR0014641A (de)
CA (1) CA2379575C (de)
CZ (1) CZ2002880A3 (de)
DE (1) DE60024115T2 (de)
DK (1) DK1218374T3 (de)
EA (1) EA005368B1 (de)
EE (1) EE05109B1 (de)
ES (1) ES2248114T3 (de)
HK (1) HK1048306B (de)
HU (1) HUP0203312A3 (de)
IL (2) IL148876A0 (de)
MX (1) MXPA02003199A (de)
NO (1) NO324792B1 (de)
NZ (1) NZ517424A (de)
PL (1) PL212237B1 (de)
SI (1) SI1218374T1 (de)
SK (1) SK287058B6 (de)
TR (1) TR200200789T2 (de)
UA (1) UA74796C2 (de)
WO (1) WO2001023378A1 (de)
ZA (1) ZA200201509B (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1088821A1 (de) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksamer Sulfonamid Derivate
EP1088822A1 (de) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksame Sulfonyl Hydrazid-Derivate
EP1193256A1 (de) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmazeutisch aktive Benzolsulfonamidderivate als JNK-Proteininhibitoren
EP1193268A1 (de) 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmazeutisch aktive Sulfonamidderivate mit sowohl lipophilen als auch ionisierbaren Gruppen als Inhibitoren von Protein-JunKinasen
EP1193267A1 (de) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksame hydrophile Sulfonamidderivate zur Verwendung als Proteinjunkinasehemmer
CA2436526C (en) 2000-12-13 2010-10-19 Wyeth Heterocyclic sulfonamide inhibitors of beta amyloid production
US6657070B2 (en) 2000-12-13 2003-12-02 Wyeth Production of chirally pure α-amino acids and N-sulfonyl α-amino acids
EP1380576B1 (de) 2001-04-16 2009-11-25 Eisai R&D Management Co., Ltd. 1h-indazolverbindungen die jnk hemmen
EP1409483B1 (de) * 2001-07-23 2008-12-31 Laboratoires Serono SA Arylsulfonamidderivate als hemmer c-jun-terminaler kinasen (jnk)
PA8557501A1 (es) 2001-11-12 2003-06-30 Pfizer Prod Inc Benzamida, heteroarilamida y amidas inversas
WO2003042190A1 (en) 2001-11-12 2003-05-22 Pfizer Products Inc. N-alkyl-adamantyl derivatives as p2x7-receptor antagonists
IL164209A0 (en) 2002-05-31 2005-12-18 Eisai Co Ltd Pyrazole derivatives and pharmaceutical compositions containing the same
US7166622B2 (en) 2002-06-11 2007-01-23 Wyeth Substituted phenylsulfonamide inhibitors of beta amyloid production
US7071223B1 (en) 2002-12-31 2006-07-04 Pfizer, Inc. Benzamide inhibitors of the P2X7 receptor
PA8591801A1 (es) 2002-12-31 2004-07-26 Pfizer Prod Inc Inhibidores benzamidicos del receptor p2x7.
AU2004221812B2 (en) 2003-03-19 2010-02-18 Exelixis Inc. Tie-2 modulators and methods of use
KR20060002908A (ko) 2003-03-31 2006-01-09 와이어쓰 베타 아밀로이드 생산 억제제인 플루오로- 및트리플루오로알킬-함유 헤테로사이클릭 설폰아미드 및 이의유도체
WO2005025558A1 (en) * 2003-09-12 2005-03-24 Applied Reserach Systems Ars Holding N.V. Sulfonamide derivatives for the treatment of diabetes
DE602005016775D1 (de) 2004-01-16 2009-11-05 Wyeth Corp Heterocyclische, ein azol enthaltende sulfonamidinhibitoren der beta-amyloid-produktion
WO2005074921A1 (en) * 2004-02-09 2005-08-18 University Of Zurich Treatment of atherosclerosis
CN1660811A (zh) * 2004-02-27 2005-08-31 中国科学院上海药物研究所 1，4－二取代苯类化合物及其制备方法和用途
WO2005118543A1 (ja) * 2004-06-03 2005-12-15 Ono Pharmaceutical Co., Ltd. キナーゼ阻害薬およびその用途
WO2006003500A1 (en) 2004-06-29 2006-01-12 Pfizer Products Inc. Method for preparing 5-`4-(2-hydroxy-propyl)-3,5-dioxo-4,5-dihydro-3h`1,2,4!triazin-2-yl!-benzamide derivatives by deprotecting the hydroxyl-protected precursers
US7803824B2 (en) 2004-10-29 2010-09-28 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases to treat glaucoma
US20060094753A1 (en) 2004-10-29 2006-05-04 Alcon, Inc. Use of inhibitors of Jun N-terminal kinases for the treatment of glaucomatous retinopathy and ocular diseases
US20060223807A1 (en) 2005-03-29 2006-10-05 University Of Massachusetts Medical School, A Massachusetts Corporation Therapeutic methods for type I diabetes
BRPI0613042A2 (pt) 2005-07-15 2010-12-14 Serono Lab inibidores de jnk para o tratamento de endometriose
KR20080044836A (ko) 2005-07-15 2008-05-21 라보라뚜와르 세로노 에스. 에이. 자궁내막증 치료용 ｊｎｋ 억제제
AU2011265521B8 (en) * 2005-07-15 2014-05-22 Merck Serono Sa JNK inhibitors for the treatment of endometreosis
US9598669B2 (en) 2005-12-29 2017-03-21 Anthrogenesis Corporation Composition for collecting placental stem cells and methods of using the composition
EP2026802A2 (de) * 2006-06-02 2009-02-25 Laboratoires Serono SA Jnk-hemmer zur behandlung von hautkrankheiten
WO2011060321A1 (en) 2009-11-16 2011-05-19 Chdi, Inc. Transglutaminase tg2 inhibitors, pharmaceutical compositions, and methods of use thereof
US8889716B2 (en) 2011-05-10 2014-11-18 Chdi Foundation, Inc. Transglutaminase TG2 inhibitors, pharmaceutical compositions, and methods of use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1706174A3 (ru) * 1989-02-08 1995-10-10 Институт биохимии Литовской АН N-замещенные 5-фталимидонафталин-1-сульфамиды в качестве полупродуктов для получения n-замещенных аминонафталинсульфамидов
WO1991013872A1 (en) 1990-03-15 1991-09-19 The Upjohn Company Therapeutically useful heterocyclic indole compounds
US5106983A (en) 1990-04-30 1992-04-21 The United States Of America As Represented By The Secretary Of The Army Process of making carfentanil and related analgesics
US5576313A (en) 1994-08-29 1996-11-19 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5684013A (en) * 1995-03-24 1997-11-04 Schering Corporation Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US6011029A (en) * 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
AU2420897A (en) * 1996-03-29 1997-10-22 G.D. Searle & Co. Meta-substituted phenylene sulphonamide derivatives
PT923542E (pt) * 1996-05-31 2003-12-31 Upjohn Co Aminas ciclicas substituidas no arilo como ligandos selectivos de dopamina d3
US6020357A (en) * 1996-12-23 2000-02-01 Dupont Pharmaceuticals Company Nitrogen containing heteroaromatics as factor Xa inhibitors
US6043083A (en) 1997-04-28 2000-03-28 Davis; Roger J. Inhibitors of the JNK signal transduction pathway and methods of use
CA2291778A1 (en) * 1997-05-29 1998-12-03 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
DE19743435A1 (de) * 1997-10-01 1999-04-08 Merck Patent Gmbh Benzamidinderivate
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
EP1144381A2 (de) * 1998-11-25 2001-10-17 MERCK PATENT GmbH Substituierte benzo[de]isochinolin-1,3-dione
JP2003509501A (ja) * 1999-09-23 2003-03-11 アストラゼネカ・アクチエボラーグ 治療薬キナゾリン化合物
EP1088822A1 (de) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksame Sulfonyl Hydrazid-Derivate
EP1088821A1 (de) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmazeutisch wirksamer Sulfonamid Derivate
EP1088815A1 (de) 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Pharmaceutisch Aktive Sulfonyl-Aminosäurederivate
US6506901B2 (en) * 2000-07-17 2003-01-14 Wyeth Substituted 2-(S)-hydroxy-3-(piperidin-4-yl-methylamino)-propyl ethers and substituted 2-aryl-2-(R)-hydroxy-1-(piperidin-4-yl-methyl)-ethylamine β-3 adrenergic receptor agonists

Also Published As

Publication number Publication date
HK1048306B (zh) 2005-06-10
HUP0203312A2 (hu) 2003-01-28
NO20021530L (no) 2002-03-26
ES2248114T3 (es) 2006-03-16
EA200200417A1 (ru) 2002-10-31
AU7307400A (en) 2001-04-30
DK1218374T3 (da) 2005-12-27
BG106527A (en) 2003-02-28
JP2012121904A (ja) 2012-06-28
BG65797B1 (bg) 2009-12-31
AU777708B2 (en) 2004-10-28
PL212237B1 (pl) 2012-08-31
EE05109B1 (et) 2008-12-15
JP5015397B2 (ja) 2012-08-29
PL354169A1 (en) 2003-12-29
MXPA02003199A (es) 2002-10-31
BR0014641A (pt) 2002-06-11
NZ517424A (en) 2004-01-30
HUP0203312A3 (en) 2003-02-28
NO20021530D0 (no) 2002-03-26
EP1218374A1 (de) 2002-07-03
EP1218374B1 (de) 2005-11-16
EP1088821A1 (de) 2001-04-04
SK287058B6 (sk) 2009-10-07
ZA200201509B (en) 2003-04-30
CN1377347A (zh) 2002-10-30
CA2379575A1 (en) 2001-04-05
SI1218374T1 (sl) 2006-02-28
HK1048306A1 (en) 2003-03-28
JP2003510319A (ja) 2003-03-18
TR200200789T2 (tr) 2002-08-21
EA005368B1 (ru) 2005-02-24
CA2379575C (en) 2011-03-15
US8012995B1 (en) 2011-09-06
DE60024115T2 (de) 2006-07-27
NO324792B1 (no) 2007-12-10
DE60024115D1 (de) 2005-12-22
CN1189467C (zh) 2005-02-16
UA74796C2 (en) 2006-02-15
AR031531A1 (es) 2003-09-24
EE200200165A (et) 2003-04-15
KR100827533B1 (ko) 2008-05-06
CZ2002880A3 (cs) 2002-06-12
IL148876A (en) 2010-11-30
SK5802002A3 (en) 2002-08-06
IL148876A0 (en) 2002-09-12
KR20020062282A (ko) 2002-07-25
WO2001023378A1 (en) 2001-04-05

Similar Documents

Publication Publication Date Title
DE60024115D1 (de) Pharmazeutisch wirksamer sulfonamid derivaten
PT1175408E (pt) Derivados sulfonamida
PT1220856E (pt) Compostos farmaceuticamente activos
NO20003721D0 (no) Farmasøytisk aktivt morfolinol
NL350038I2 (nl) Herbicidaal actieve 3-hydroxy-4-aryl-5-oxopyrazolinederivaten
DE60009747D1 (de) Admantan-derivate
ATE293104T1 (de) Thiazolylamid-derivate
PT1237857E (pt) Novos derivados fenalquiloxi-fenilo
ATE257148T1 (de) Propargyletherderivate
NO20013684D0 (no) Substituerte fenetylaminderivater
ATE374747T1 (de) Monofluoralkylderivate
ATE273272T1 (de) Mevinolinderivate
DE60006703D1 (de) 4-hydroxybiphenylhydrazid-derivate
ATE293592T1 (de) Resorcinderivate
DE59902159D1 (de) Aktiver mikromischer
DE69907845D1 (de) Sulfonamid-Derivate
TR200002831A3 (tr) Kinolin-4-Il türevleri I
DE60025348D1 (de) Ethansulfonyl-piperidin-derivate
DE60001736D1 (de) 1-trifluorotmethyl-4-hydroxy-7-piperidinyl-aminomethylchroman-derivate
NO20004816D0 (no) Ny farmasøytisk formulering
ATE269328T1 (de) 1-cycloalkylpyrazolyl-benzoyl-derivate
DE60045878D1 (de) Pharmazeutisch aktive Isoindolin-Derivate
DE60006104D1 (de) Cinnamoylaminoalkyl-substituierte benzenesulfonamid-derivate
SE9901854D0 (sv) New pharmaceutically active compounds
IS8740A (is) Lyfjafræðilega virkt morfólínól

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1218374

Country of ref document: EP

EEFA Change of the company name